Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Follicular Lymphoma
Regimen:
GVD (gemcitabine + pegylated liposomal doxorubicin + vinorelbine tartrate)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Second-line therapy and subsequent therapy for AITL, INCLUDING NODAL PTCL, TFH, and FTCL and ALCL….Intention to proceed to transplant: GVD (gemcitabine, vinorelbine, liposomal doxorubicin) added as a category 2A
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login